Latest Becker's muscular dystrophy Stories
Grant Funds Work of Ronald G. Victor, M.D.
SOUTH PLAINFIELD, N.J., March 30, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer. Dr. Spiegel served previously as Chief Medical Officer of Schering-Plough.
AMSTERDAM, March 7, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy (DMD).
Efforts over decade result in $192 million in Duchenne-specific federal investment HACKENSACK, N.J., Feb.
It's a gene called DOT1L, and if you donâ€™t have enough of the DOT1L enzyme, you could be at risk for some types of heart disease.
SOUTH PLAINFIELD, N.J. and HACKENSACK, N.J., Feb. 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy (DBMD).
A novel potential therapy based on a natural human protein significantly slows muscle damage and improves function in mice who have the same genetic mutation as boys with the most common form of muscular dystrophy.
SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /PRNewswire/ -- PTC Therapeutics, Inc.
SOUTH PLAINFIELD, N.J., Dec.
HACKENSACK, N.J., Nov.
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.